Seminars in Oncology
Volume 33 , Pages 15-22 , April 2006

Novel Therapeutic Strategies With Alemtuzumab for Chronic Lymphocytic Leukemia

  • Kanti R. Rai

      Affiliations

    • Dr Rai has received research grant support from Berlex, and honoraria from Berlex and Genentech.
    • Corresponding Author InformationAddress reprint requests to: Kanti Rai, MD, Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040

References 

  1. Jemal A , Murray T , Ward E , et al.   Cancer Statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  2. Rai KR , Chiorazzi N . Determining the clinical course and outcome in chronic lymphocytic leukemia . N Engl J Med . 2003;348:1797–1799
  3. French Cooperative Group on Chronic Lymphocytic Leukemia . French Cooperative Group on Chronic Lymphocytic Leukemia (Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials) . Leuk Lymphoma . 1994;13:449–456
  4. Jaksic B , Brugiatelli M , Krc I , et al.   High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial . International Society for Chemo-Immunotherapy, Vienna. Cancer . 1997;79:2107–2114
  5. Leporrier M , Chevret S , Cazin B , et al.   Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients . Blood . 2001;98:2319–2325
  6. Keating MJ , O’Brien S , Lerner S , et al.   Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy . Blood . 1998;92:1165–1171
  7. Johnson S , Smith AG , Loffler H , et al.  The French Cooperative Group on CLL   Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia . Lancet . 1996;347:1432–1438
  8. Rai KR , Peterson BL , Appelbaum FR , et al.   Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N Eng J Med . 2000;343:1750–1757
  9. Genini D , Budihardjo I , Plunkett W , et al.   Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway . J Biol Chem . 2000;275:29–34
  10. Genini D , Adachi S , Chao Q , et al.   Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria . Blood . 2000;96:3537–3543
  11. Shieh SY , Ikeda M , Taya Y , et al.   DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 . Cell . 1997;91:325–334
  12. Thornton PD , Gruszka-Westwood AM , Hamoudi RA , et al.   Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia . Hematol J . 2004;5:47–54
  13. Fenaux P , Preudhomme C , Lai JL , et al.   Mutations of the p53 gene in B-cell chronic lymphocytic leukemia (A report on 39 cases with cytogenetic analysis) . Leukemia . 1992;6:246–250
  14. Callet-Bauchu E , Salles G , Gazzo S , et al.   Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders (Frequent occurrence of dicentric rearrangements and possible association with adverse outcome) . Leukemia . 1999;13:460–468
  15. Lozanski G , Heerema NA , Flinn IW , et al.   Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions . Blood . 2004;103:3278–3281
  16. Keating MJ , O’Brien S , Kontoyiannis D , et al.   Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia . Leuk Lymphoma . 2002;43:1755–1762
  17. Österborg A , Dyer MJ , Bunjes D , et al.  European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia   Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia . J Clin Oncol . 1997;15:1567–1574
  18. Rawstron A , Davies C , Evans P , et al.   CAMPATH-1H therapy for patients with refractory chronic lymphocytic leukaemia . Blood . 1997;90:2356; (abstr)
  19. Stilgenbauer S , Scherer K , Krobler A , et al.   Campath-1H in refractory CLL-Complete remission despite p53 gene mutation . Blood . 2001;98:3211; (abstr)
  20. McCune SL , Gockerman JP , Moore JO , et al.   Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia . Leuk Lymphoma . 2002;43:1007–1011
  21. Rai KR , Freter CE , Mercier RJ , et al.   Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine . J Clin Oncol . 2002;20:3891–3897
  22. Ferrajoli A , O’Brien SM , Cortes JE , et al.   Phase II study of alemtuzumab in chronic lymphoproliferative disorders . Cancer . 2003;98:773–778
  23. Rai KR , Keating MJ , Coutre S , et al.   Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial . Blood . 2002;100:3165; (abstr)
  24. Keating MJ , Flinn I , Jain V , et al.   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (Results of a large international study) . Blood . 2002;99:3554–3561
  25. Stilgenbauer S , Winkler D , Krober A , et al.   Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL (Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG)) . Blood . 2004;104:478; (abstr)
  26. Hale G , Rebello P , Brettman L , et al.   Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration . Blood . 2004;104:948–955
  27. Lundin J , Kimby E , Bjorkholm M , et al.   Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) . Blood . 2002;100:768–773
  28. Hillmen P , Skotnicki A , Robak T , et al.   Preliminary safety and efficacy report of randomized trial of alemtuzumab vs. chlorambucil as front-line in 297 patients with progressive B-cell chronic lymphocytic leukemia . Blood . 2004;104:2505
  29. Rawstron AC , Kennedy B , Evans PA , et al.   Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy . Blood . 2001;98:29–35
  30. Moreton P , Kennedy B , Lucas G , et al.   Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival . J Clin Oncol . 2005;23:2971–2979
  31. Rai KR , Byrd J , Peterson B , et al.   A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease (Cancer and Leukemia Group B (CALGB) study 19901) . Blood . 2002;100:772; (abstr)
  32. Rai KR , Byrd J , Peterson B , et al.   Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL) (CALGB Study 19901) . Blood . 2003;102:2506; (abstr)
  33. O’Brien S , Gribben JG , Thomas DA , et al.   Alemtuzumab for minimal residual disease in CLL . Blood . 2003;102:371; (abstr)
  34. O’Brien SM , Kantarjian HM , Thomas DA , et al.   Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia . Cancer . 2003;98:2657–2663
  35. Montillo M , Tedeschi A , Rossi V , et al.   Consolidation with alemtuzumab after a response to fludarabine in patients with CLL. Confirmation of the efficacy to purge residual disease . Leuk Lymphoma . 2005;46(suppl 1):S93; (abstr)
  36. Wendtner CM , Ritgen M , Schweighofer CD , et al.   Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) . Leukemia . 2004;18:1093–1101
  37. Ritgen M , Schweighofer C , Fingerle-Rowson G , et al.   Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions–Update on randomized phase III trial of the German CLL Study Group (GCLLSG) . Blood . 2004;104:2506; (abstr)
  38. Elter T , Borchmann P , Schulz H , et al.   Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (Results of a Phase II trial) . J Clin Oncol . 2005;23:7024–7031
  39. Dohner H , Stilgenbauer S , Benner A , et al.   Genomic aberrations and survival in chronic lymphocytic leukemia . N Eng J Med . 2000;343:1910–1916
  40. Dohner H , Fishcer K , Bentz M , et al.   p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic-B-cell leukemias . Blood . 1995;85:1580–1589
  41. El Rouby S , Thomas A , Costin D , et al.   p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression . Blood . 1993;82:3452–3459
  42. Sturm I , Bosanquet AG , Hermann S , et al.   Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy . Cell Death Diff . 2003;10:477–484
  43. Byrd JC , Smith L , Hackbarth ML , et al.   Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab . Cancer Res . 2003;63:36–38
  44. Byrd JC , Gribben JG , Peterson B , et al.   Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL) (Preliminary justification for risk-adapted therapy) . Blood . 2004;104:476; (abstr)
  45. Grever MR , Lucas DM , Dewald GW , et al.   Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely implicated by high risk genetic features (results from ECOG 2997) . Blood . 2004;104:3487; (abstr)
  46. Lucas DM , Dewald GW , Neuberg DS , et al.   Clinical, laboratory, and treatment outcome characteristics of chronic lymphocytic leukemia (CLL) patients with p53mutations or del(17p) enrolled in a prospective phase III clinical trial (Short progression free survival, irrespective of fludarabine-based treatment used) . Blood . 2004;104:949; (abstr)
  47. Catovsky D , Richards S , Matutes E , et al.   Response to therapy and survival in CLL is influenced by genetic markers (preliminary analysis from the LRF CLL4 trial) . Blood . 2004;104:13; (abstr)
  48. Stilgenbauer S , Winkler D , Krober A , et al.   Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL (Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG)) . Blood . 2004;104:478; (abstr)
  49. Cortelezzi A , Pasquini MC , Sarina B , et al.   A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia . Haematologica . 2005;90:410–412
  50. Osuji N , Giudice ID , Matutes E , et al.   Alemtuzumab for chronic lymphocytic leukemia with and without p53 deletions . Blood . 2004;104:2510; (abstr)
  51. Kimby E , Wallblom A , Merup M , et al.   Alemtuzumab (Campath-1H) S.C. is effective in patients with B-CLL with adverse chromosomal aberrations . In: Abstracts of the 10th Congress of the European Hematology Association . 2005;p. 1258; (abstr)
  52. Rai KR , Janson D , Driscoll N , et al.   Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL) . Blood . 2002;103:1099; (abstr)
  53. Thieblemont C , Bouafia F , Hornez E , et al.   Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic leukemia (B-CLL/SLL) . Leuk Lymphoma . 2004;45:711–714

PII: S0093-7754(06)00057-1

doi: 10.1053/j.seminoncol.2006.01.025

Seminars in Oncology
Volume 33 , Pages 15-22 , April 2006

Article Tools

* Image Usage & Resolution